RxDoctor Payments Data

Patricia Patton, APRN

Psychiatric/Mental Health · Prestonsburg, KYNPI 1790300218

Payments from drug & device makers

$2,135in general payments, 2019–2025

Across 118 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$492
  • AbbVie$400
  • Ironshore Pharmaceuticals Inc.$323
  • Neurocrine Biosciences, Inc.$195
  • Alkermes, Inc.$167
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$158
  • plus $400 from 8 others

What the payments were for

  • Food & beverage$2,135100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,135 in reported general payments places this provider in the 70th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$9,815
Medicare patients
23
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$143,150
VraylarCariprazine Hcl46$75,182
RexultiBrexpiprazole40$57,251
TrintellixVortioxetine Hydrobromide22$12,036
Lurasidone Hcl21$7,490
Paliperidone ErPaliperidone12$4,365
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$2,056
Vilazodone Hcl13$1,684
Quetiapine Fumarate ErQuetiapine Fumarate33$1,471
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine54$1,155
Atomoxetine Hcl13$1,044
Buspirone Hcl105$1,042
Duloxetine Hcl67$864
Clonazepam146$782
Gabapentin59$777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$195$143,15017 claims
AbbVieVraylar$400$75,18246 claims
Otsuka America Pharmaceutical, Inc.Rexulti$492$57,25140 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$15$12,03622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Prestonsburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →